Medx Health

Medx Health FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Medx Health (MDX.V) as of Oct 18, 2026 is 59.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 68.73 % — a change of -13.68% (lower).

FCF Conversion

59.33 %

YoY

-13.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Medx Health is 2025 59.33 % . FCF Conversion Rate (FCF/EBITDA) of Medx Health was 2024 68.73 % . It decreases by -13.68% lower compared to the previous year.

The Medx Health FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
62.52 CAD
Jan 1, 2019
40.57 CAD
Jan 1, 2020
91.09 CAD
Jan 1, 2021
85.15 CAD
Jan 1, 2022
54.56 CAD
Jan 1, 2023
74.71 CAD
Jan 1, 2024
68.73 CAD
Jan 1, 2025
59.33 CAD
The Medx Health FCF Conversion history
YEARFCF ConversionYoY
59.33 %-13.68%
68.73 %-8.00%
74.71 %+36.94%
54.56 %-35.93%
85.15 %-6.52%
91.09 %+124.52%
40.57 %-35.11%
62.52 %-31.86%
91.76 %-8.23%
99.98 %-7.77%
108.41 %-75.77%
447.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medx Health Stock analysis

What does Medx Health do? Medx Health Corp, trading under the ticker MDX.V, is a Canadian company headquartered in Mississauga, Ontario. The company went public on February 12, 2008, and operates within the Health Care sector, specifically in the Health Care industry. Medx Health Corp develops, manufactures, and sells medical devices and software. Its primary focus is on skin health, utilizing SIAscopy technology for skin-related screening tools. The company offers a telemedicine platform called SIAscopy on DermSecure, which integrates its SIAscopy scanning technology for web-based operations. Products include SIAMETRICS, SIMSYS, and MoleMate, which are hand-held devices that use light-based technology to examine moles and lesions up to two millimeters beneath the skin surface in a pain-free, non-invasive manner. These devices are designed for the rehabilitation market, providing phototherapy treatments using low-level laser and light-emitting diode technology to address pain and tissue damage. The company's offerings are centered around non-invasive skin screening and phototherapeutic applications, targeting both diagnostic and therapeutic needs within the health care sector. Medx Health Corp's products are intended for medical professionals and patients seeking advanced, non-invasive solutions for skin health management and rehabilitation. Medx Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medx Health stock

FCF Conversion Rate (FCF/EBITDA) of Medx Health is 59.33 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Medx Health changed from 68.73 % to 59.33 %, representing a -13.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Medx Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Medx Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medx Health

All Key Metrics — Medx Health